tert-Butyl (5-chloro-3-hydroxypyridin-2-yl)carbamate

Catalog No. :
ACZDMO051
CAS No. :
1609402-46-1
Molecular Formula :
C10H13ClN2O3
Molecular Weight :
244.68

IUPAC Name:tert-butyl (5-chloro-3-hydroxypyridin-2-yl)carbamate

tert-Butyl (5-chloro-3-hydroxypyridin-2-yl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g97%$104.00Login to see priceInquiryInquiry
10g97%$184.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl (5-chloro-3-hydroxypyridin-2-yl)carbamate
IUPAC Nametert-butyl (5-chloro-3-hydroxypyridin-2-yl)carbamate
MDL No.MFCD27935389
Molecular FormulaC10H13ClN2O3
Molecular Weight244.68
SMILESO=C(OC(C)(C)C)NC1=NC=C(Cl)C=C1O
InChI KeyUCZOCPZOKRYOGX-UHFFFAOYSA-N
SynonymN-(5-Chloro-3-hydroxy-2-pyridinyl)carbamic acid 1,1-dimethylethyl ester;tert-Butyl (5-chloro-3-hydroxypyridin-2-yl)carbamate;2-(Boc-amino)-5-chloro-3-hydroxypyridine;N-(5-Chloro-3-hydroxy-2-pyridinyl)carbamic acid;Carbamic acid, N-(5-chloro-3-hydroxy-2-pyridinyl)-, 1,1-dimethylethyl ester;N-(5-Chloro-3-hydroxy-2-pyridinyl)carbamic acid 1,1-dimethyl...
CAS No.1609402-46-1
PubChem CID73554938

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACZDMO051 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACVOZN276 route compound structure diagram
    ACVOZN27640966-87-8 In Stock
  4. Then
  5. ACZDMO051 route product structure diagram
    ACZDMO0511609402-46-1
Inquiry

2. ACZDMO051 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACZDMO051 route product structure diagram
    ACZDMO0511609402-46-1
Inquiry

Comments (0)